|
Oct 1
|
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
|
|
Sep 30
|
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
|
Jul 25
|
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
|
|
Jun 18
|
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
|
|
Apr 25
|
Altimmune Statement on the Passing of Dr. Stephen Harrison
|
|
Jan 2
|
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
|
|
Nov 30
|
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
|